Indegene and SynPhNe join hands to bring relief to stroke and TBI victims worldwide

SynPhNe uses a real-time neuroplasticity training model to help the body and brain recover function together. Real-time, synchronized EEG and EMG signals are captured during tasks and activities to create a self-correcting learning loop, making it possible to self-administer physical therapy, occupational therapy, and neuro therapy protocols at home, after initial training with a therapist.

Both the stroke and TBI markets are growing rapidly. Currently, the stroke management industry is estimated to be over $37 billion, and it is projected to reach more than $59 billion by 2032¹. More than 6 million people worldwide each year are pegged as stroke survivors. The traumatic brain injury market is also growing with more than 69 million people worldwide sustaining a TBI each year².

Sabi Bivas, President of SynPhNe Health, Inc., said “More people are being impacted by neurological conditions each year. To help them get better access to effective treatment, we are excited to work with Indegene to bring our treatment option to the market. Indegene’s focus on technology and providing future-ready healthcare aligns with our mission. We will leverage their modern commercialization model to try and bring relief to many more people around the world suffering from strokes, TBIs, and other neurological conditions.”

Timothy Moore, Senior Vice President, Emerging Biotech and Key Accounts, Indegene, said, “We are excited to join hands with SynPhNe to support their early commercialization and bring this device to market. We will use our modern go-to-market model to drive pricing strategy and develop a strategic launch plan that coordinates education and marketing efforts based on our deep expertise in market research and brand planning.”